View Item 

Show simple item record

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

dc.contributor.authorPatel, Jai N.en_US
dc.contributor.authorJiang, Chenen_US
dc.contributor.authorHertz, Daniel L.en_US
dc.contributor.authorMulkey, Flora A.en_US
dc.contributor.authorOwzar, Kourosen_US
dc.contributor.authorHalabi, Susanen_US
dc.contributor.authorRatain, Mark J.en_US
dc.contributor.authorFriedman, Paula N.en_US
dc.contributor.authorSmall, Eric J.en_US
dc.contributor.authorCarducci, Michael A.en_US
dc.contributor.authorMahoney, John F.en_US
dc.contributor.authorKelley, Michael J.en_US
dc.contributor.authorMorris, Michael J.en_US
dc.contributor.authorKelly, William K.en_US
dc.contributor.authorMcLeod, Howard L.en_US
dc.date.accessioned2015-04-02T15:12:09Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-04-01en_US
dc.identifier.citationPatel, Jai N.; Jiang, Chen; Hertz, Daniel L.; Mulkey, Flora A.; Owzar, Kouros; Halabi, Susan; Ratain, Mark J.; Friedman, Paula N.; Small, Eric J.; Carducci, Michael A.; Mahoney, John F.; Kelley, Michael J.; Morris, Michael J.; Kelly, William K.; McLeod, Howard L. (2015). "Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)." Cancer 121(7): 1025-1031.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110822
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherChapman & Hallen_US
dc.subject.otherbevacizumaben_US
dc.subject.otherprostateen_US
dc.subject.othercanceren_US
dc.subject.otherrisken_US
dc.subject.othervenousen_US
dc.subject.otherarterialen_US
dc.subject.otherthromboembolismen_US
dc.titleBevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110822/1/cncr29169.pdf
dc.identifier.doi10.1002/cncr.29169en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferencePrandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6: 401 ‐ 410.en_US
dc.identifier.citedreferenceSatagopan JM, Ben‐Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91: 1229 ‐ 1235.en_US
dc.identifier.citedreferenceChappell R. Competing risk analyses: how are they different and why should you care? Clin Cancer Res. 2012; 18: 2127 ‐ 2129.en_US
dc.identifier.citedreferenceAltman DG. Practical Statistics for Medical Research. London, UK: Chapman & Hall; 1991.en_US
dc.identifier.citedreferenceCox DR. Regression models and life‐tables. J R Stat Soc B. 1972; 34: 187 ‐ 220.en_US
dc.identifier.citedreferenceKelly WK, Halabi S, Carducci M, et al. Randomized, double‐blind, placebo‐controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration‐resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012; 30: 1534 ‐ 1540.en_US
dc.identifier.citedreferenceHurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011; 29: 1757 ‐ 1764.en_US
dc.identifier.citedreferenceMinor DR. Risk of venous thromboembolism with bevacizumab in cancer patients [letter]. JAMA. 2009; 301: 1434; author reply 1435–1436.en_US
dc.identifier.citedreferenceNalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta‐analysis. JAMA. 2008; 300: 2277 ‐ 2285.en_US
dc.identifier.citedreferenceRanpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta‐analysis of randomized controlled trials. Acta Oncol. 2010; 49: 287 ‐ 297.en_US
dc.identifier.citedreferenceKhorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy‐associated thrombosis. Blood. 2008; 111: 4902 ‐ 4907.en_US
dc.identifier.citedreferenceLyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2189 ‐ 2204.en_US
dc.identifier.citedreferenceVan Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population‐based PCBaSe Sweden. Lancet Oncol. 2010; 1: 450 ‐ 458.en_US
dc.identifier.citedreferenceHurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335 ‐ 2342.en_US
dc.identifier.citedreferenceEscudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa‐2a for treatment of metastatic renal cell carcinoma: a randomised, double‐blind phase III trial. Lancet. 2007; 370: 2103 ‐ 2111.en_US
dc.identifier.citedreferenceSaltz LB, Clarke S, Diaz‐Rubio E, et al. Bevacizumab in combination with oxaliplatin‐based chemotherapy as first‐line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013 ‐ 2019.en_US
dc.identifier.citedreferenceSandler A, Gray R, Perry MC, et al. Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer. N Engl J Med. 2006; 355: 2542 ‐ 2550.en_US
dc.identifier.citedreferenceFriedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733 ‐ 4740.en_US
dc.identifier.citedreferenceCrino L, Dansin E, Garrido P, et al. Safety and efficacy of first‐line bevacizumab‐based therapy in advanced non‐squamous non‐small‐cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 1: 733 ‐ 740.en_US
dc.identifier.citedreferenceHochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first‐line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008; 26: 3523 ‐ 3529.en_US
dc.identifier.citedreferenceScappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 1232 ‐ 1239.en_US
dc.identifier.citedreferenceSchutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011; 22: 1404 ‐ 1412.en_US
dc.identifier.citedreferenceVan Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first‐line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009; 20: 1842 ‐ 1847.en_US
dc.identifier.citedreferenceHeit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population‐based case‐control study. Arch Intern Med. 2000; 160: 809 ‐ 815.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29169.pdf
Size:
195.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.